-
Innovation Ranking
NewInnovation Ranking – Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc (Aldeyra Therapeutics), is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, an aldehyde trap for the treatment of allergic conjunctivitis and dry eye disease; ADX-2191 to treat proliferative vitreoretinopathy and intraocular lymphoma; and ADX-103/10X for the treatment of retinal disease. Aldeyra Therapeutics utilizes reactive aldehyde species (RASP), dihydrofolate reductase (DHFR) and chaperome (CHP) inhibition for advancing its pipeline products. The company’s drug candidates offer treatment for inflammation and genetic...
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Marstacimab
Empower your strategies with our Net Present Value Model: Pfizer Inc's Marstacimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Aldeyra Therapeutics Inc’s Reproxalap
Empower your strategies with our Net Present Value Model: Aldeyra Therapeutics Inc's Reproxalap report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Allergic Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Allergic Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Allergic Asthma Drug Details: Acloproxalap (ADX-629) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Typhella in Typhoid Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Typhella in Typhoid Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Typhella in Typhoid Fever Drug Details: Typhella is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Sicca Syndrome (Sjogren) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Sicca Syndrome (Sjogren) Drug Details: Acloproxalap (ADX-629) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Atopic Dermatitis (Atopic Eczema) Drug Details: Acloproxalap (ADX-629)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Esophageal Cancer Drug Details: Donafenib tosylate (Zepsun)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Chronic Cough
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Chronic Cough report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Chronic Cough Drug Details: Acloproxalap (ADX-629) is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Tagtociclib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tagtociclib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tagtociclib in Triple-Negative Breast Cancer (TNBC) Drug Details: Tagtociclib (PF-07104091)...